Cambridge, MA-based Faze Medicines announced its company launch on 10 December and plans to use its $81m series A financing to support preclinical research programs in amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Third Rock Ventures led the series A, which also included investments from Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments.
Founded by four academic scientists and experts in the field of biomolecular condensates and liquid-liquid phase transitions, Faze’s executive leadership team is helmed by interim CEO Cary Pfeffer, a partner at Third Rock Ventures and a Faze board member
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?